Showing 1261-1270 of 10735 results for "".
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- Smoke Exposure Associated With Higher Odds of Pediatric Hidradenitis Suppurativahttps://practicaldermatology.com/news/smoke-exposure-associated-with-higher-odds-of-pediatric-hidradenitis-suppurativa/2488418/Active and passive smoke exposure were associated with higher odds of hidradenitis suppurativa (HS) among pediatric and adolescent patients in a retrospective case-control study published in Pediatric Dermatology.
- Ultra-Processed Foods May Influence Pediatric Acne Through mTORC1 Signaling: Studyhttps://practicaldermatology.com/news/ultra-processed-foods-may-influence-pediatric-acne-through-mtorc1-signaling-study/2488415/Ultra-processed foods may contribute to pediatric acne through metabolic, inflammatory, and microbiome-related pathways, according to a comprehensive review published in the International Journal of Molecular Sciences. Researchers examined current evidence connecting ultra-processed foods
- Omalizumab Shows Median 3.1-Year Drug Survival in Chronic Urticariahttps://practicaldermatology.com/news/omalizumab-shows-median-31-year-drug-survival-in-chronic-urticaria/2488414/Omalizumab demonstrated a median drug survival of more than 3 years among patients with chronic urticaria (CU), with successful disease control rather than adverse events emerging as a common reason for treatment discontinuation, according to a systematic review an
- PISCES: Adalimumab Biosimilar Achieves PASI75 in 81% of Children With Severe Psoriasishttps://practicaldermatology.com/news/pisces-adalimumab-biosimilar-achieves-pasi75-in-81-of-children-with-severe-psoriasis/2488405/The first prospective study of an adalimumab biosimilar in Chinese children with severe plaque psoriasis showed significant clinical response through 16 weeks and no reported adverse events. The multicenter PISCES study, published in Dermatology and Therapy, included 80 patients a
- PCA SKIN Launches Acne Control Prebiotic Gel Cleanserhttps://practicaldermatology.com/news/pca-skin-launches-acne-control-prebiotic-gel-cleanser/2488391/PCA SKIN has launched Acne Control Prebiotic Gel Cleanser, a daily cleanser designed for acne-prone skin that pairs acne-fighting ingredients with technology intended to support the skin microbiome. The gel-to-lather cleanser contains 2% salicylic acid to help clear and prevent acne breako
- AI Analysis Maps Environmental and Immune Signatures in Pediatric ADhttps://practicaldermatology.com/news/ai-analysis-maps-environmental-and-immune-signatures-in-pediatric-atopic-dermatitis/2488367/A machine learning (ML)-based analysis of environmental, immune, and transcriptomic data identified distinct protective and susceptibility clusters associated with pediatric atopic dermatitis (AD) among AmaXhosa children in South Africa. Published in PLoS Medicine, the observation
- DRESS: Tofacitinib Shows Glucocorticoid-Sparing Potentialhttps://practicaldermatology.com/news/dress-tofacitinib-shows-glucocorticoid-sparing-potential/2488346/Adding tofacitinib to systemic glucocorticoid therapy was associated with reduced glucocorticoid exposure and faster clinical improvement among patients with drug reaction with eosinophilia and systemic symptoms (DRESS), according to a study published online in the
- Consensus Statement: JAK Inhibitors Emerge as Primary Therapy for Severe Alopeciahttps://practicaldermatology.com/news/consensus-statement-jak-inhibitors-emerge-as-primary-therapy-for-severe-alopecia/2488332/A US expert consensus provides a standardized treatment framework for adults with severe alopecia areata (AA), placing oral Janus kinase (JAK) inhibitors at the center of long-term disease management.
- Cardamonin Shows Antifibrotic Activity in Human Keloid Fibroblasts: Studyhttps://practicaldermatology.com/news/cardamonin-shows-antifibrotic-activity-in-human-keloid-fibroblasts-study/2488327/Cardamonin demonstrated antifibrotic activity in human keloid fibroblasts by suppressing transforming growth factor β1 (TGF-β1)/Smad signaling, according to new in vitro research in the Journal of Drugs in Dermatology.